RB and cyclin dependent kinase pathways: defining a distinction between RB and p16 loss in lung cancer
The DOI matches its Crossref record; 79 of the 80 references it cites were found in a registry or an index.
Abstract
The genetic components of the RB:CDK:cyclin:p16 tumor suppressor pathway undergo mutational and epigenetic alterations in a wide range of human cancers and serve as critical targets for inactivation by the transforming oncoproteins of several DNA tumor viruses. Lung cancer has been a useful model system for these studies as it was the first tumor to demonstrate an important role for RB in the genesis of a common adult malignancy and was also the first human cancer to demonstrate genetic evidence for a multi-component RB:p16 tumor suppressor pathway. Lung tumorigenesis, however, is a complex disease process that requires longstanding carcinogen exposure in order to acquire somatic alterations at many distinct genetic loci. Understanding the multifunctional properties of RB to regulate cell proliferation, differentiation, and apoptosis and how they relate to the sequential accumulation of other clonal gene defects will be essential in order to understand the specific patterns of gene inactivation observed in different subtypes of lung cancer and to fulfill the promise of 'molecular target' therapeutics.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A clear example that RB and p16 mutations are not equivalent comes from the observations that RB is mutated in most, if not all cases of SCLC, whereas p16 mutations are never found in this lung cancer type but are prevalent in non-SCLC, a different type of lung cancer167.”
From Cellular mechanisms of tumour suppression by the retinoblastoma gene (2008) · cites this paper as [167]
In the citing paper
“A clear example that RB and p16 mutations are not equivalent comes from the observations that RB is mutated in most, if not all cases of SCLC, whereas p16 mutations are never found in this lung cancer type but are prevalent in non-SCLC, a different type of lung cancer167.”
From Cellular mechanisms of tumour suppression by the retinoblastoma gene (2008) · cites this paper as [167]
In the citing paper
“A clear example that RB and p16 mutations are not equivalent comes from the observations that RB is mutated in most, if not all cases of SCLC, whereas p16 mutations are never found in this lung cancer type but are prevalent in non-SCLC, a different type of lung cancer167.”
From Cellular mechanisms of tumour suppression by the retinoblastoma gene (2008) · cites this paper as [167]
Citations
Cites
CDK inhibitors: positive and negative regulators of G1-phase progression
Sherr, C. J., & Roberts, J. M. (1999) · Genes & Development · doi:10.1101/gad.13.12.1501 · Cited by 6,115 · cited 2×
“…p21/p27/p57 Cip/Kip family of CDK2:cyclin E inhibitors (Grimison et al., 2000; Jiang et al., 1998; Sherr and Roberts, 1999), seemingly to both sequester inhibitory activity away from CDK2:cyclin E complexes and, perhaps, to stabilize CDK4/6:cyclin D activity (Sherr and Roberts, 1999) (Figure 1).”
BackgroundThe retinoblastoma protein and cell cycle control
Weinberg, R. A. (1995) · Cell · doi:10.1016/0092-8674(95)90385-2 · Cited by 4,862
A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4.
Serrano, M., Hannon, G. J., & Beach, D. (1993) · Nature · doi:10.1038/366704a0 · Cited by 3,650 · cited 1×
“…et al., 1994), as a common site for homozygous deletions in tumor cell lines (Kamb et al., 1994), and as a negative regulator for the CDK4/6 kinase (Serrano et al., 1993) which phosphorylates RB in late G1, suggested that the p16 gene could be an important target for mutations in a wide range of…”
BackgroundA human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma
Friend, S. H., Bernards, R., Rogelj, S., Weinberg, R. A., Rapaport, J. M., Albert, D. M., & Dryja, T. P. (1986) · Nature · doi:10.1038/323643a0 · Cited by 2,948 · cited 1×
“Nonetheless, shortly after the validation of the RB gene as the locus that underlies the development of both familial and sporadic retinoblastoma (Friend et al., 1986; Lee et al., 1987), mutational inactivation of the RB gene was identified in approximately 90% of the common adult malignancy, small…”
BackgroundA cell cycle regulator potentially involved in genesis of many tumor types
Kamb, A., Gruis, N. A., Weaver-Feldhaus, J., Liu, Q., Harshman, K., Tavtigian, S. V., Stockert, E., Day, R. S., Johnson, B. E., & Skolnick, M. H. (1994) · Science · doi:10.1126/science.8153634 · Cited by 2,751 · cited 2×
“The almost simultaneous description of the p16 gene as the locus conferring susceptibility familial melanoma (Kamb et al., 1994), as a common site for homozygous deletions in tumor cell lines (Kamb et al., 1994), and as a negative regulator for the CDK4/6 kinase (Serrano et al., 1993) which…”
BackgroundMost human carcinomas of the exocrine pancreas contain mutant c-K-ras genes
Almoguera, C., Shibata, D., Forrester, K., Martin, J., Arnheim, N., & Perucho, M. (1988) · Cell · doi:10.1016/0092-8674(88)90571-5 · Cited by 2,114 · cited 1×
“…lung, and thyroid, they are rarely detected in the endocrine tumors that arise from these same organs and may occur in 0% of medullary thyroid cancer and in 0% of neuroendocrine small cell lung cancer (Almoguera et al., 1988; Bockhorn et al., 2000; Capella et al., 1996; Mitsudomi et al., 1991).”
BackgroundMerlo, A., Herman, J. G., Mao, L., Lee, D. J., Gabrielson, E., Burger, P. C., Baylin, S. B., & Sidransky, D. (1995) · Nature Medicine · doi:10.1038/nm0795-686 · Cited by 1,986 · cited 1×
“…in identifying acquired somatic p16 mutations in tumors resulted from the unexpected observation that the p16 gene preferentially undergoes tumor-specific epigenetic gene silencing through promoter and exon 1 hypermethylation (Herman et al., 1995; Merlo et al., 1995; Otterson et al., 1995).”
BackgroundEffects of an Rb mutation in the mouse
Jacks, T., Fazeli, A., Schmitt, E. M., Bronson, R. T., Goodell, M. A., & Weinberg, R. A. (1992) · Nature · doi:10.1038/359295a0 · Cited by 1,755 · cited 1×
“For example, the major defect underlying the embryonic lethality of RB null mice can be primarily localized to selected regions of ectopic cell proliferation/apoptosis within neural tissues (Jacks et al., 1992; Lee et al., 1992).”
BackgroundThe Molecular Genetics of Cancer
Bishop, J. M. (1987) · Science · doi:10.1126/science.3541204 · Cited by 1,688
Mice deficient for Rb are nonviable and show defects in neurogenesis and haematopoiesis
Lee, E. Y.-H. P., Chang, C.-Y., Hu, N., Wang, Y.-C. J., Lai, C.-C., Herrup, K., Lee, W.-H., & Bradley, A. (1992) · Nature · doi:10.1038/359288a0 · Cited by 1,265 · cited 1×
“For example, the major defect underlying the embryonic lethality of RB null mice can be primarily localized to selected regions of ectopic cell proliferation/apoptosis within neural tissues (Jacks et al., 1992; Lee et al., 1992).”
Background
Cited by
van Meerbeeck, J. P., Fennell, D. A., & De Ruysscher, D. K. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60165-7 · Cited by 1,237
Cellular mechanisms of tumour suppression by the retinoblastoma gene
Burkhart, D. L., & Sage, J. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2399 · Cited by 974
Small cell lung cancer: Where do we go from here?
Byers, L. A., & Rudin, C. M. (2015) · Cancer · doi:10.1002/cncr.29098 · Cited by 636
Targeting protein prenylation for cancer therapy
Berndt, N., Hamilton, A. D., & Sebti, S. M. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3151 · Cited by 614
Byers, L. A., Wang, J., Nilsson, M. B., Fujimoto, J., Saintigny, P., Yordy, J., Giri, U., Peyton, M., Fan, Y. H., Diao, L., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0112 · Cited by 557
Yachida, S., Vakiani, E., White, C. M., Zhong, Y., Saunders, T., Morgan, R., de Wilde, R. F., Maitra, A., Hicks, J., DeMarzo, A. M., et al. (2012) · American Journal of Surgical Pathology · doi:10.1097/pas.0b013e3182417d36 · Cited by 534
“Thus, combined loss of p53 and Rb function appears to be a necessary step for the development of this tumor, and alterations of the RB1 gene may play an important role in terms of manifestation of neuroendocrine features.(6,24,26) Interestingly, overexpression of Bcl-2 protein was observed in all 9 small cell NECs and…”
BackgroundJackman, D. M., & Johnson, B. E. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67569-1 · Cited by 503
Nrf2 Enhances Cell Proliferation and Resistance to Anticancer Drugs in Human Lung Cancer
Homma, S., Ishii, Y., Morishima, Y., Yamadori, T., Matsuno, Y., Haraguchi, N., Kikuchi, N., Satoh, H., Sakamoto, T., Hizawa, N., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2822 · Cited by 418
Tailoring to RB: tumour suppressor status and therapeutic response
Knudsen, E. S., & Knudsen, K. E. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2401 · Cited by 344
Clinical and Biological Features of Neuroendocrine Prostate Cancer
Yamada, Y., & Beltran, H. (2021) · Current Oncology Reports · doi:10.1007/s11912-020-01003-9 · Cited by 305
Small-Cell Carcinomas of the Gastrointestinal Tract: A Review
Brenner, B., Tang, L. H., Klimstra, D. S., & Kelsen, D. P. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.09.075 · Cited by 294
Sato, M., Vaughan, M. B., Girard, L., Peyton, M., Lee, W., Shames, D. S., Ramirez, R. D., Sunaga, N., Gazdar, A. F., Shay, J. W., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2521 · Cited by 263
“Absence of expression or structural abnormality of Rb protein is seen in >90% of small-cell lung cancers (SCLC) and loss of p16 protein expression by several mechanisms, including methylation or homozygous deletion of p16 , is seen in >70% of non-SCLC (NSCLC), both of which result in the inactivation of this pathway (…”
BackgroundJi, H., Zhao, X., Yuza, Y., Shimamura, T., Li, D., Protopopov, A., Jung, B. L., McNamara, K., Xia, H., Glatt, K. A., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0510284103 · Cited by 257
Lung Cancer Cell Lines as Tools for Biomedical Discovery and Research
Gazdar, A. F., Girard, L., Lockwood, W. W., Lam, W. L., & Minna, J. D. (2010) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djq279 · Cited by 239
Simultaneous Identification of Multiple Driver Pathways in Cancer
Leiserson, M. D. M., Blokh, D., Sharan, R., & Raphael, B. J. (2013) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1003054 · Cited by 236
“suppressor, and thus mutations that target either CCND1 or RB1 are thus important for proliferation in cancer [44].”
BackgroundFranco, J., Witkiewicz, A. K., & Knudsen, E. S. (2014) · Oncotarget · doi:10.18632/oncotarget.2270 · Cited by 207
“Furthermore, analysis of mutual-exclusivity in cancer demonstrates that there is a pronounced reciprocal relationship between the loss of p16ink4a, deregulation of CDK4/6, and loss of RB [25, 27, 28].”
BackgroundClinical and molecular features of treatment‐related neuroendocrine prostate cancer
Akamatsu, S., Inoue, T., Ogawa, O., & Gleave, M. E. (2018) · International Journal of Urology · doi:10.1111/iju.13526 · Cited by 163
The epigenetics of ovarian cancer drug resistance and resensitization
Balch, C., Huang, T. H.-M., Brown, R., & Nephew, K. P. (2004) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2004.05.025 · Cited by 160
Reciprocal expression of INSM1 and YAP1 defines subgroups in small cell lung cancer
McColl, K., Wildey, G., Sakre, N., Lipka, M. B., Behtaj, M., Kresak, A., Chen, Y., Yang, M., Velcheti, V., Fu, P., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.20572 · Cited by 158
“RB1 expression was mostly associated with a wild-type (wt) exon mutation status and its functionality in YAP1-positive cell lines was suggested by decreased or absent CDKN2A/2B expression, previously shown as an alternate mechanism to disable the RB1 pathway in lung cancer [19].”
BackgroundMolecular footprints of human lung cancer progression
Yokota, J., & Kohno, T. (2004) · Cancer Science · doi:10.1111/j.1349-7006.2004.tb02203.x · Cited by 139
Witkiewicz, A. K., & Knudsen, E. S. (2014) · Breast Cancer Research · doi:10.1186/bcr3652 · Cited by 125
“Importantly, this pathway demonstrates mutually exclusive disruption in cancer [21-24].”
BackgroundPalakurthy, R. K., Wajapeyee, N., Santra, M. K., Gazin, C., Lin, L., Gobeil, S., & Green, M. R. (2009) · Molecular Cell · doi:10.1016/j.molcel.2009.10.009 · Cited by 122
“By contrast, knockdown of the retinoblastoma (RB1) protein, a known NSCLC tumor suppressor (reviewed in Kaye, 2002; Wikman and Kettunen, 2006) that is expressed in A549 cells (Figure S8), had no significant effect on tumor growth rate (Figure 5B).”
ResultRetinoblastoma Tumor Suppressor: Where Cancer Meets the Cell Cycle
Knudsen, E. S., & Knudsen, K. E. (2006) · Experimental Biology and Medicine · doi:10.1177/153537020623100713 · Cited by 104
Wang, H. L., & Lu, D. W. (2004) · The American Journal of Surgical Pathology · doi:10.1097/00000478-200407000-00009 · Cited by 106
“cancers, mutational inactivation of the Rb gene occurs in approximately 90% of the cases.(19) This is in marked contrast to”
Febres‐Aldana, C. A., Chang, J. C., Ptashkin, R. N., Wang, Y., Gedvilaite, E., Baine, M. K., Travis, W. D., Ventura, K., Bodd, F. M., Yu, H. A., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-1115 · Cited by 98
Brenner, B., Tang, L. H., Shia, J., Klimstra, D. S., & Kelsen, D. P. (2007) · Seminars in Oncology · doi:10.1053/j.seminoncol.2006.10.022 · Cited by 94
Liu, Y., Clem, B., Zuba-Surma, E. K., El-Naggar, S., Telang, S., Jenson, A. B., Wang, Y., Shao, H., Ratajczak, M. Z., Chesney, J., et al. (2009) · Cell Stem Cell · doi:10.1016/j.stem.2009.02.015 · Cited by 92
“Moreover, the RB1 family is regulated by phosphorylation mediated by cdks, and in tumors where RB1 is not mutated the pathway is inactivated by hyperphosphorylation of family members (Kaye, 2002; Du and Pogoriler, 2006; Frolov and Dyson, 2004; Lowe and Sherr, 2003).”
BackgroundWang, J., Lee, J. J., Wang, L., Liu, D. D., Lu, C., Fan, Y.-H., Hong, W. K., & Mao, L. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0652 · Cited by 94
Nuclear overexpression of the E2F3 transcription factor in human lung cancer
Cooper, C. S., Nicholson, A. G., Foster, C. S., Dodson, A. R., Edwards, S. E., Fletcher, A., Roe, T., Clark, J., Joshi, A., Norman, A. R., et al. (2006) · Lung Cancer · doi:10.1016/j.lungcan.2006.07.005 · Cited by 88
Unfavorable prognosis of CRTC1‐MAML2 positive mucoepidermoid tumors with CDKN2A deletions
Anzick, S. L., Chen, W.-D. D., Park, Y. S., Meltzer, P. S., Bell, D., El‐Naggar, A. K., & Kaye, F. J. (2009) · Genes Chromosomes and Cancer · doi:10.1002/gcc.20719 · Cited by 87
“…for earlystage disease (Brock et al., 2008) and where inactivation of the RB/CDKN2A pathway is detected in essentially all advanced stage cases (Kaye, 2002), there is less known about the role of CDKN2A in MEC or other subtypes of malignant salivary gland cancers (Cerilli et al., 1999; Li et…”
BackgroundSelf-citationOkuda, Y., Nakamura, H., Yoshida, K., Enomoto, H., Uyama, H., Hirotani, T., Funamoto, M., Ito, H., Everett, A. D., Hada, T., et al. (2003) · Cancer Science · doi:10.1111/j.1349-7006.2003.tb01397.x · Cited by 98
Campa, D., Müller, P., Edler, L., Knoefel, L. F., Barale, R., Heußel, C. P., Thomas, M., Canzian, F., & Risch, A. (2012) · International Journal of Cancer · doi:10.1002/ijc.27567 · Cited by 99
New anti-cancer strategies: Epigenetic therapies and biomarkers
Balch, C. (2005) · Frontiers in bioscience · doi:10.2741/1668 · Cited by 78
Wikman, H., & Kettunen, E. (2006) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.6.4.515 · Cited by 72
“11 Kaye FJ. RB and cyclin dependent kinase pathways: defining a distinction between RB and p16 loss in lung cancer.”
BackgroundInfluentialMolecular classification and molecular genetics of human lung cancers
Meyerson, M. M., Franklin, W. A., & Kelley, M. J. (2004) · Seminars in Oncology · doi:10.1053/j.seminoncol.2003.12.009 · Cited by 78
CDK4/6 inhibitors: a brief overview and prospective research directions
Adon, T., Shanmugarajan, D., & Kumar, H. Y. (2021) · RSC Advances · doi:10.1039/d1ra03820f · Cited by 71
Genetic alterations in poorly differentiated endocrine carcinomas of the gastrointestinal tract
Pizzi, S., Azzoni, C., Bassi, D., Bottarelli, L., Milione, M., & Bordi, C. (2003) · Cancer · doi:10.1002/cncr.11621 · Cited by 66
“This same correlation has been shown to exist in a wide variety of human malignancies,(29) including advanced lung carcinomas.(9,27,30) p16 and Rb belong to the same cell cycle regulatory pathway, along with cyclin D1 and cyclin-dependent kinase 4 (Cdk4).”
BackgroundAnalysis of cell cycle regulator proteins in non-small cell lung cancer
Esposito, V., Baldi, A., Tonini, G., Vincenzi, B., Santini, M., Ambrogi, V., Mineo, T. C., Persichetti, P., Liuzzi, G., Montesarchio, V., et al. (2003) · Journal of Clinical Pathology · doi:10.1136/jcp.57.1.58 · Cited by 69
Beyond IDH-Mutation: Emerging Molecular Diagnostic and Prognostic Features in Adult Diffuse Gliomas
Mirchia, K., & Richardson, T. E. (2020) · Cancers · doi:10.3390/cancers12071817 · Cited by 75
Oncolytic virotherapy for small-cell lung cancer induces immune infiltration and prolongs survival
Kellish, P. C., Shabashvili, D. E., Rahman, M. M., Nawab, A., Guijarro, M. V., Zhang, M., Cao, C., Moussatché, N., Boyle, T. A., Antonia, S. J., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci121323 · Cited by 64
“We selected human SCLC as a solid tumor model for preclinical testing for MYXV therapy because (a) relapsed SCLC is incurable (8), (b) RB and p53 are targeted for mutational inactivation in essentially 100% of SCLC (34) and PTEN loss and/or AKT1 activation are concurrently observed in a large subset of tumor samples (…”
MethodSelf-citationJiang, F., Caraway, N. P., Li, R., & Katz, R. L. (2005) · Oncogene · doi:10.1038/sj.onc.1208459 · Cited by 60
“Cell proliferation involves the activation of CDK complexes, the inactivation of the retinoblastoma tumor suppressor protein, and the accumulation of E2F transcription factors (Volm et al., 1998; Kaye, 2002).”
BackgroundThe Retinoblastoma Protein Is Required for Ras-Induced Oncogenic Transformation
Williams, J. P., Stewart, T. A., Li, B., Mulloy, R., Dimova, D. K., & Classon, M. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.26.4.1170-1182.2006 · Cited by 64
“However, in those cases, RB pathway disruption does not involve the direct loss of the pRB protein, but instead involves either loss of the Cdk inhibitor p16, amplification of cyclin D1, or mutation of cdk4 (33, 37, 39, 61, 72, 79).”
BackgroundZuo, J., Brewer, D. S., Arlt, V. M., Cooper, C. S., & Phillips, D. H. (2014) · BMC Genomics · doi:10.1186/1471-2164-15-880 · Cited by 59
“For example Cdkn2a is generally involved in cell cycle control but can induce apoptosis in lung [78].”
BackgroundSolta, A., Ernhofer, B., Boettiger, K., Megyesfalvi, Z., Heeke, S., Hoda, M. A., Lang, C., Aigner, C., Hirsch, F. R., Schelch, K., et al. (2024) · Molecular Cancer · doi:10.1186/s12943-024-01953-9 · Cited by 65
“Therefore, the loss of TP53 (75%-90% of patients [25]) and RB1 (nearly 100% [26]) is confirmed in the vast majority of cases.”
BackgroundSphingolipids in the DNA damage response
Carroll, B. L., Donaldson, J. C., & Obeid, L. M. (2014) · Advances in Biological Regulation · doi:10.1016/j.jbior.2014.11.001 · Cited by 58
“…results in hypophosphorylation of Rb (retinoblastoma protein), which prevents the cell from progressing through its critical cycle checkpoints (Kaye, 2002). p53 also drives an apoptotic pathway in the DDR, through BAX-mediated activation of caspase-3 (Polyak et al., 1997; Yin et al., 1997).”
p16INK4A Positively Regulates Cyclin D1 and E2F1 through Negative Control of AUF1
Al‐Khalaf, H. H., Çolak, D., Al‐Saif, M., AlBakheet, A., Hendrayani, S., Al‐Yousef, N., Kaya, N., Khabar, K. S. A., & Aboussekhra, A. (2011) · PLoS ONE · doi:10.1371/journal.pone.0021111 · Cited by 57
“Indeed, the disruption of this pathway is a mandatory requirement for 100% of lung cancer [3].”
BackgroundKitamura, H., Yazawa, T., Sato, H., Okudela, K., & Shimoyamada, H. (2009) · Endocrine Pathology · doi:10.1007/s12022-009-9072-4 · Cited by 50
“protein is brought about by excessive cyclin-dependent kinase (Cdk) activity on account of p16/Ink4a silencing, cyclin D1 overexpression, and/or other mechanisms [2, 7, 14].”
BackgroundGopalan, P. K., Villegas, A. G., Cao, C., Pinder-Schenck, M. C., Chiappori, A., Hou, W., Zajac‐Kaye, M., Ivey, A. M., & Kaye, F. J. (2018) · Oncotarget · doi:10.18632/oncotarget.26424 · Cited by 53
“In the case of small cell lung cancer (SCLC), almost 90% of tumors specifically target the RB gene with loss-of-function somatic mutations, and the remaining tumors show genetic or epigenetic alterations in either CDKN2a/p16 or other cryptic gene loci within the RB tumor suppressor pathway [6, 7].”
BackgroundSelf-citationHo, V. M., Schaffer, B. E., Karnezis, A. N., Park, K. S., & Sage, J. (2009) · Oncogene · doi:10.1038/onc.2008.491 · Cited by 55
“Kaye FJ. (2002).”
Lee, J., Park, J., Kwon, O., Lee, T.-H., Nakano, I., Miyoshi, H., Chun, K., Park, M., Lee, H. J., Kim, S. U., et al. (2014) · Neuro-Oncology · doi:10.1093/neuonc/nou145 · Cited by 48
“Induction of cyclin dependent kinase inhibitors or pro-apoptotic factors through a tumor surveillance network, following p53 activation, reactivates retinoblastoma (Rb) to cause cell cycle arrest or induces apoptosis to avoid oncogenic transformation.(4,5) Therefore, abrogation of the innate cellular defensive mechani…”
BackgroundReplication competent Semliki Forest virus prolongs survival in experimental lung cancer
Määttä, A., Mäkinen, K. T., Ketola, A., Liimatainen, T., Yongabi, F. N., Vähä-Koskela, M. J. V., Pirinen, R. T., Rautsi, O., Pellinen, R., Hinkkanen, A., et al. (2008) · International Journal of Cancer · doi:10.1002/ijc.23646 · Cited by 52
“characteristic to most cancer cells, including lung cancer.(29) Thus, Ad5-D24TK-GFP was intended both as a positive control for oncolysis of the lung cancer cells and as comparison for oncolytic efficacy.”
BackgroundTumor Suppressors and Cell-Cycle Proteins in Lung Cancer
Baldi, A., Luca, A. D., Esposito, V., Campioni, M., Spugnini, E. P., & Citro, G. (2011) · Pathology Research International · doi:10.4061/2011/605042 · Cited by 53
Neuro-endocrine tumours of the lung. A review of relevant pathological and molecular data
Righi, L., Volante, M., Rapa, I., Scagliotti, G. V., & Papotti, M. G. (2007) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-007-0445-0 · Cited by 46
“Mutations in RB1 gene with loss of function of the retinoblastoma gene product have also been detected in most SCLC [13, 24].”
BackgroundBarayan, R., Ran, X., & Lok, B. H. (2020) · Journal of Thoracic Disease · doi:10.21037/jtd.2020.03.89 · Cited by 47
“cell cycle checkpoint, and TP53, a gene critical for multiple DNA damage response (DDR) pathways (5-11).”
BackgroundBreathing new insights into the role of mutant p53 in lung cancer
Chen, T., Ashwood, L. M., Kondrashova, O., Strasser, A., Kelly, G., & Sutherland, K. D. (2025) · Oncogene · doi:10.1038/s41388-024-03219-6 · Cited by 46
Marzoq, A. J., Mustafa, S. A., Heidrich, L., Hoheisel, J. D., & Alhamdani, M. S. S. (2019) · Scientific Reports · doi:10.1038/s41598-019-41740-x · Cited by 49
Vékony, H., Raaphorst, F. M., Otte, A. P., van Lohuizen, M., Leemans, C. R., van der Waal, I., & Bloemena, E. (2008) · Journal of Clinical Pathology · doi:10.1136/jcp.2007.054262 · Cited by 41
“It has been discovered that in cases of overexpression/ amplification of cyclin D1 or mutation/deletion of pRb, p16 levels can accumulate as a result of oncogenic stress without causing proliferative arrest.(43) 44”
BackgroundDib, A., Peterson, T. R., Raducha-Grace, L., Zingone, A., Zhan, F., Hanamura, I., Barlogie, B., Shaughnessy, J. D., & Kuehl, W. M. (2006) · Cell Division · doi:10.1186/1747-1028-1-23 · Cited by 40
“The increased expression of p18 in proliferative MM cells is reminiscent of the increased expression of p16INK4a in small cell lung cancer tumors that have inactivated the RB-1 gene[37].”
BackgroundSärkioja, M., Kanerva, A., Salo, J., Kangasniemi, L., Eriksson, M. R., Raki, M., Ranki, T., Hakkarainen, T., & Hemminki, A. (2006) · Cancer · doi:10.1002/cncr.22209 · Cited by 40
“A promising approach for development of CRAds is based on utilization of a 24-basepair (bp) deletion in the E1 gene that allows viruses to replicate preferentially in cells in which the Rb/p16 pathway is inactive, which could include most human cancer cells, including NSCLCs.(17,18) Recently, it is been demonstrated t…”
InfluentialCress, W. D., Engel, B. E., & Santiago‐Cardona, P. G. (2014) · Cell Health and Cytoskeleton · doi:10.2147/chc.s28079 · Cited by 51
“Interestingly, lung cancer survival rate triples to 18% in the non-SCLC (NSCLC) subtype, which usually bears wild-type RB1 alleles but instead exhibits preferential loss of the p16 locus with consequent Rb hyperphosphorylation.(42) The differences in survival rates between SCLC and NSCLC suggest that increased aggress…”
Sosa-García, B., Gündüz, V., Vázquez‐Rivera, V., Cress, W. D., Wright, G. M., Bian, H., Hinds, P. W., & Santiago‐Cardona, P. G. (2010) · PLoS ONE · doi:10.1371/journal.pone.0013954 · Cited by 40
“This is an important question that must be addressed in follow-up studies since mutations in CDK4, cyclin D, and p16ink4a are linked to the molecular etiology of a wider spectrum of human tumors than mutational inactivation of pRb itself [48].”
BackgroundEsposito, V., Baldi, A., Luca, A. D., Tonini, G., Vincenzi, B., Santini, D., Persichetti, P., Mancini, A., Citro, G., Baldi, F., et al. (2005) · Journal of Clinical Pathology · doi:10.1136/jcp.2004.023531 · Cited by 38
Molecular analysis of the Ink4a/Rb1–Arf/Tp53 pathways in radon-induced rat lung tumors
Bastide, K., Guilly, M., Bernaudin, J., Joubert, C., Lectard, B., Levalois, C., Malfoy, B., & Chevillard, S. (2008) · Lung Cancer · doi:10.1016/j.lungcan.2008.06.007 · Cited by 38
Small cell carcinoma of the extrahepatic bile duct: Case report and immunohistochemical analysis
Kuraoka, K., Taniyama, K., Fujitaka, T., Nakatsuka, H., Nakayama, H., & Yasui, W. (2003) · Pathology International · doi:10.1046/j.1440-1827.2003.01575.x · Cited by 36
Role of cell‐cycle regulators in lung cancer
Caputi, M., Russo, G. M., Esposito, V., Mancini, A., & Giordano, A. (2005) · Journal of Cellular Physiology · doi:10.1002/jcp.20424 · Cited by 40
“…of cyclin D1 and cyclin D2, key regulators of pRb phosphorylation, and downregulation of cyclin-dependent kinase inhibitors p15, p21, p19, and p57 (Kawamata et al., 1995; Rusin et al., 1996; Gazzeri et al., 1998; Keum et al., 1999; Jin et al., 2001; Shoji et al., 2002; Singhal et al., 2003a).”
BackgroundManagement of Small Cell Lung Cancer: Progress and Updates
Altan, M., & Chiang, A. C. (2015) · The Cancer Journal · doi:10.1097/ppo.0000000000000148 · Cited by 39
Wang, Y., Zheng, Z., Zhang, J., Wang, Y., Kong, R., Liu, J., Zhang, Y., Deng, H., Du, X., & Ke, Y. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.655597 · Cited by 39
“Rb loss is also found in a variety of cancers such as small cell lung carcinoma ( 90%) (4) and osteosarcoma ( 50%) (1, 5, 6).”
BackgroundRecent Advances in the Clinical Translation of Small-Cell Lung Cancer Therapeutics
Das, S., & Samaddar, S. (2025) · Cancers · doi:10.3390/cancers17020255 · Cited by 33
Cyclin-dependent kinase inhibitors for the treatment of lung cancer
Qin, A., Reddy, H. G., Weinberg, F. D., & Kalemkerian, G. P. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2020.1738385 · Cited by 37
“given the almost universal loss of functional RB in SCLC [76].”
BackgroundThe challenge of classifying poorly differentiated tumours in the lung
Wallace, W. A. (2009) · Histopathology · doi:10.1111/j.1365-2559.2008.03181.x · Cited by 31
Imai, M. A., Oda, Y., Oda, M., Nakanishi, I., & Kawahara, E. (2004) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-003-0538-3 · Cited by 31
“The incidence of aberration of the RB gene and protein in non-small cell carcinoma is lower than that in small cell carcinoma, and it has been believed that loss of RB function is due to the loss of function of RB protein, which is regulated by phosphorylation status (Kaye 2002).”
BackgroundVékony, H., Röser, K., Löning, T., Raaphorst, F. M., Leemans, C. R., van der Waal, I., & Bloemena, E. (2008) · Histopathology · doi:10.1111/j.1365-2559.2008.03184.x · Cited by 30
Adaptive Transcriptional Responses by CRTC Coactivators in Cancer
Tasoulas, J., Rodón, L., Kaye, F. J., Montminy, M., & Amelio, A. L. (2019) · Trends in cancer · doi:10.1016/j.trecan.2018.12.002 · Cited by 29
Self-citationXiong, J., Barayan, R., Louie, A. V., & Lok, B. H. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.07.008 · Cited by 35
Role of Mammalian Ecdysoneless in Cell Cycle Regulation
Kim, J. H., Gurumurthy, C. B., Naramura, M., Zhang, Y., Dudley, A. T., Doglio, L. T., Band, H., & Band, V. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.030551 · Cited by 35
Myong, N. (2008) · Cancer Research and Treatment · doi:10.4143/crt.2008.40.2.45 · Cited by 29
Boonmars, T., Wu, Z., Boonjaruspinyo, S., Pinlaor, S., Nagano, I., Takahashi, Y., Kaewsamut, B., & Yongvanit, P. (2009) · Parasitology Research · doi:10.1007/s00436-009-1548-0 · Cited by 31
“The reported loss of RB1 in human cancer cases was various, for example, >90% in lung cancer (Salgia et al. 1998; Yuan et al. 1999; Kaye 2002; Deeb et al. 2007), 30–”
BackgroundMethylation and expression of the p16INK4A tumor suppressor gene in multiple myeloma
Dib, A., Barlogie, B., Shaughnessy, J. D., & Kuehl, W. M. (2007) · Blood · doi:10.1182/blood-2006-09-049510 · Cited by 25
Mizuarai, S., Machida, T., Kobayashi, T., Komatani, H., Itadani, H., & Kotani, H. (2011) · Molecular Cancer · doi:10.1186/1476-4598-10-31 · Cited by 23
“The activity of RB1 is mainly regulated by the upstream CDKN2A/CCND1 pathway [3-5].”
BackgroundCDK4/6 Inhibitors in Cancer Therapy: A Novel Treatement Strategy for Bladder Cancer
Pan, Q., Sathe, A., Black, P. C., Goebell, P. J., Kamat, A. M., Schmitz‐Dräger, B. J., & Nawroth, R. (2017) · Bladder Cancer · doi:10.3233/blc-170105 · Cited by 28
“For instance, Rb deficient cells can regulate the G1/S transition independent of the CDK4/6-Rb pathway and these inhibitors might be ineffective despite Rb reconstitution [26, 68, 69].”
BackgroundWang, H. L., & Lu, D. W. (2004) · Modern Pathology · doi:10.1038/modpathol.3800112 · Cited by 24
Pandey, P., Khan, F., Upadhyay, T. K., & Sharangi, A. B. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032236 · Cited by 24
“A growing number of malignancies are being treated with CDK inhibition because it stops cell proliferation [12,13] The discovery of “key regulators of the cell cycle” made by Leland H.”
BackgroundFor Whom the Bell Tolls: Susceptibility to Common Adult Cancers in Retinoblastoma Survivors
Kaye, F. J., & Harbour, J. W. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh080 · Cited by 23
Self-citationNarrative review of challenges in the management of advanced neuroendocrine prostate cancer
Okasho, K., Ogawa, O., & Akamatsu, S. (2021) · Translational Andrology and Urology · doi:10.21037/tau-20-1131 · Cited by 22
“Aberrations in the Rb and p53 pathways are also observed in small cell lung cancer (43,44).”
BackgroundSignificantly mutated genes and regulatory pathways in SCLC—a meta-analysis
Sundaresan, V., Lin, V. T. G., Liang, F., Kaye, F. J., Kawabata‐Iwakawa, R., Shiraishi, K., Kohno, T., Yokota, J., & Zhou, L. J. (2017) · Cancer Genetics · doi:10.1016/j.cancergen.2017.05.003 · Cited by 20
“SCLC is known to exhibit very high mutation rates and genomic instability, possibly linked to tobacco carcinogens [3].”
Self-citationAlterations in thep16INK4a/Cyclin D1/RBPathway in Gastrointestinal Tract Endocrine Tumors
Li, A. F., Li, A. C.-H., Tsay, S.-H., Li, W.-Y., Liang, W.-Y., & Chen, J.-Y. (2008) · American Journal of Clinical Pathology · doi:10.1309/tllvxk9hva89chpe · Cited by 20
Kitamura, H., Yazawa, T., Okudela, K., Shimoyamada, H., & Sato, H. (2008) · The Open Pathology Journal · doi:10.2174/1874375700802010106 · Cited by 18
“Rb protein is functionally inactivated through phosphorylation by cyclin dependent kinase (Cdk) 4/6/cyclin D1, Cdk2/cyclin E, and Cdk2/cyclin A, whose activities are controlled and repressed by the members of the Kip and Ink4 families [15, 16].”
BackgroundInfluentialIwasa, A., Oda, Y., Kurihara, S., Ohishi, Y., Yasunaga, M., Nishimura, I., Takagi, E., Kobayashi, H., Wake, N., & Tsuneyoshi, M. (2008) · Pathology International · doi:10.1111/j.1440-1827.2008.02307.x · Cited by 18
p16-Positive Small Cell Neuroendocrine Carcinoma of the Endometrium
Melgoza, F. U., Brewster, W. R., Wilczynski, S. P., & Rutgers, J. K. L. (2006) · International Journal of Gynecological Pathology · doi:10.1097/01.pgp.0000189242.11404.ae · Cited by 18
“p16 is an upstream regulator of the phosphorylation of Rb (16).”
BackgroundPRIM2 Promotes Cell Cycle and Tumor Progression in p53-Mutant Lung Cancer
Wang, T., Tang, T., Jiang, Y., He, T., Qi, L., Chang, H., Qiao, Y., Sun, M., Shan, C., Zhu, X., et al. (2022) · Cancers · doi:10.3390/cancers14143370 · Cited by 17
“p53 and RB are well-known tumor suppressors, and they are often mutated and inactive in lung cancer [7,8,11,12].”
BackgroundLiu, S., Wang, X., Qin, W., Genchev, G. Z., & Lu, H. J. (2018) · Interdisciplinary Sciences Computational Life Sciences · doi:10.1007/s12539-018-0300-9 · Cited by 17
Gupta, S., Silveira, D. A., Mombach, J. C. M., & Hashimoto, R. F. (2025) · Proteomes · doi:10.3390/proteomes13010006 · Cited by 20
P16INK4A is required for cisplatin resistance in cervical carcinoma SiHa cells
Li, Y., Xiao, S., Liu, D., & Xue, M. (2014) · Oncology Letters · doi:10.3892/ol.2014.2814 · Cited by 18
Progressing from Gene Mutations to Cancer
Fearon, E. R., & Bommer, G. T. (2008) · Elsevier eBooks · doi:10.1016/b978-0-443-06694-8.50017-8 · Cited by 18
Kono, M., Allen, P. K., Lin, S. H., Wei, X., Jeter, M. D., Welsh, J. W., Cox, J. D., & Komaki, R. U. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.07.030 · Cited by 15
Xande, J. G., Dias, A. P., Tamura, R. E., Cruz, M. C., Brito, B., Ferreira, R. A., Strauss, B. E., & Costanzi-Strauss, E. (2019) · Gene Therapy · doi:10.1038/s41434-019-0096-1 · Cited by 14
“non-small cell lung carcinomas maintain pRB [36], a great many cases would be candidates for a therapy involving CDKN2A gene transfer.”
BackgroundSurprising Dependency for Retinoblastoma Protein in Ras-Mediated Tumorigenesis
DeGregori, J. V. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.26.4.1165-1169.2006 · Cited by 18
“In contrast, preferential inactivation of INK4A (frequently by gene methylation) in precursors for NSCLC may provide a positive selective pressure for Ras*.”
BackgroundInfluentialMarquez, S. B., Rai, S. K., Gramling, S. J. B., Lu, L., & Reisman, D. (2016) · Oncoscience · doi:10.18632/oncoscience.333 · Cited by 14
“To date, the RB1 pathway in human cancers has been reported to be disrupted only by loss of expression of CDKN2A or RB1, as well as by CDK4/CCND1 overexpression [48], even though SWI/SNF is known to be an essential cofactor for RB1 function [16, 17].”
BackgroundSubbiah, S. P., Nam, A., Garg, N., Behal, A., Kulkarni, P., & Salgia, R. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9082433 · Cited by 15
Ribeiro, E. A., & Maleki, Z. (2020) · Journal of the American Society of Cytopathology · doi:10.1016/j.jasc.2020.12.003 · Cited by 12
Metadata
- Authors
- Kaye, F. J.
- Affiliations
- National Institutes of Health (US)
- Corresponding author
- Kaye, Frederic J
- ORCID
- Kaye, Frederic J
- Venue
- Oncogene
- Published
- 2002-10-04
- Volume
- 21
- Issue
- 45
- Pages
- 6908-6914
- ISSN
- 0950-9232 (ISSN-L)
- 1476-5594
- OpenAlex
- W2081412587
- Cited by
- 153
- References
- 80
- Citations by year
- 2026: 2 · 2025: 5 · 2024: 3 · 2023: 2 · 2022: 3 · 2021: 5 · 2020: 7 · 2019: 5 · 2018: 5 · 2017: 7 · 2016: 2 · 2015: 5 · 2014: 13 · 2013: 5 · 2012: 4
- FWCI
- 0.74
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Oncogene (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Keywords
- retinoblastoma protein, cyclin-dependent kinases, p16, tumor suppressor pathways, lung cancer, lung carcinogenesis, gene inactivation, epigenetic modifications, DNA tumor viruses, carcinogen exposure, targeted therapy
- MeSH terms
- Humans, Lung Neoplasms, Proto-Oncogene Proteins, Genes, Retinoblastoma, Gene Deletion, Carcinoma, Small Cell, Cyclin-Dependent Kinases, Genes, p16, Cyclin-Dependent Kinase 4
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.